retatrutide clinical trials brazil Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation 💉 A triple-action once-weekly injection

All in Group 3 received an ICD

Holland & Barrett Glucomannan & Chromium 90 Capsules | H&B

The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed

If your provider specifically recommends Ozempic based on your comorbidities, that clinical judgment is worth following